Rochester, NY, United States of America

Elora Supersad

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Bausch + Lomb Ireland Limited. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Elora Supersad: Innovator in Contact Lens Solutions

Introduction

Elora Supersad is a notable inventor based in Rochester, NY (US). She has made significant contributions to the field of ophthalmic solutions, particularly with her innovative patent related to contact lens treating solutions.

Latest Patents

Elora holds a patent for a contact lens treating solution that includes several key components. The solution comprises about 0.005 to about 2 wt. % of hyaluronic acid or a salt thereof, about 0.01 to about 1 wt. % of erythritol, one or more nonionic surfactants, sodium chloride, potassium chloride, or any combination thereof, and one or more buffers. This formulation aims to enhance the comfort and effectiveness of contact lens care.

Career Highlights

Elora is currently employed at Bausch + Lomb Ireland Limited, a company renowned for its commitment to eye health and vision care. Her work at this organization has allowed her to focus on developing innovative solutions that improve the user experience for contact lens wearers.

Collaborations

Elora collaborates with talented professionals in her field, including her coworkers John Michael Duex and Vicki Barniak. Their combined expertise contributes to the advancement of eye care technologies.

Conclusion

Elora Supersad's contributions to contact lens solutions exemplify her dedication to innovation in the field of ophthalmic care. Her patent reflects a significant advancement that benefits users and enhances their experience with contact lenses.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…